SAN DIEGO--(BUSINESS WIRE)--Phenovista, a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, today announced the appointment of Ellen Berg, PhD to its Scientific Advisory Board.

圣地亚哥--（商业新闻短讯）--生命科学服务公司Phenovista今天宣布任命Ellen Berg博士为其科学顾问委员会成员，该公司开发并实施基于多重高内容成像的表型分析，用于目标验证，铅优化和作用机制研究。

Dr. Berg is the Founder of Alto Predict and is an expert in human cell-based in vitro assays and platforms for drug discovery and chemical safety applications..

Berg博士是Alto Predict的创始人，是基于人类细胞的体外测定和药物发现和化学安全应用平台的专家。。

“We are thrilled to announce that Ellen is joining our Scientific Advisory Board,” said James Evans, PhD, Chief Executive Officer of Phenovista. “She has an unmatched combination of experience in phenotypic assay development and the use of multivariate profiling to model mechanisms of action and target engagement.

Phenovista首席执行官詹姆斯·埃文斯（JamesEvans）博士表示：“我们很高兴宣布艾伦将加入我们的科学顾问委员会。”。“她在表型分析开发方面拥有无与伦比的经验，并使用多变量分析来模拟作用机制和目标参与。

We look forward to her expert counsel as we continue to expand our capabilities in these areas.”.

我们期待着她的专家顾问，因为我们将继续扩大我们在这些领域的能力。”。

Dr. Berg is a recognized leader in assay development, mechanisms of drug and disease biology, and research data management. She has a background in biopharmaceutical research and drug discovery contract research services with startup, operations, and commercialization experience. Her research interests include mechanisms of human disease biology and drug action, predictive toxicology, and research information science, including AI/ML approaches and data visualization.

Berg博士是分析开发，药物和疾病生物学机制以及研究数据管理领域公认的领导者。她拥有生物制药研究和药物发现合同研究服务的背景，具有创业、运营和商业化经验。她的研究兴趣包括人类疾病生物学和药物作用机制，预测毒理学和研究信息科学，包括AI/ML方法和数据可视化。

She works to promote FAIR data (Findable, Accessible, Interoperable and Reusable data) and the use of human-based alternatives to animals, or NAMs (Novel Alternative Methods), in biomedical research and product development. Dr. Berg received her PhD in chemistry and biology from Northwestern University..

她致力于在生物医学研究和产品开发中推广公平的数据（可查找的，可访问的，可互操作的和可重复使用的数据）以及使用基于人类的动物替代品或NAMs（新型替代方法）。伯格博士在西北大学获得了化学和生物学博士学位。。

“I have always been impressed with Phenovista’s ability to provide customers with novel biological insights and the high-quality data needed to guide, accelerate, and de-risk R&D decisions,” said Dr. Berg. “I’m excited to join their Scientific Advisory Board and work closely with the team as they continue to build upon their leadership position in the area of high-plex, high-content phenotypic assays services.”.

Berg博士说：“Phenovista能够为客户提供新颖的生物学见解和指导、加速和降低研发决策风险所需的高质量数据，这给我留下了深刻的印象。我很高兴加入他们的科学顾问委员会，并与团队密切合作，因为他们将继续巩固其在高复杂度、高内容表型分析服务领域的领导地位。”。

About Phenovista

关于Phenovista

Founded in 2014, Phenovista is a leader in the development and implementation of multiplexed, high content imaging-based phenotypic assays for biopharmaceutical clients. These assays deliver the high-quality, quantitative data needed to inform and de-risk critical R&D decisions with greater confidence.

Phenovista成立于2014年，是生物制药客户开发和实施基于多重高内容成像的表型检测的领导者。这些分析提供了所需的高质量定量数据，以更有信心地告知和降低关键研发决策的风险。

Clients gain access to novel insights related to the complex biology underlying target validation, therapeutic delivery, efficacy and safety, cytotoxicity, and mechanisms of action, increasing the likelihood of success of first-in-class drug candidates..

客户可以获得与复杂生物学相关的新颖见解，这些生物学基础包括靶标验证，治疗传递，功效和安全性，细胞毒性以及作用机制，从而增加了一流候选药物成功的可能性。。